This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies
by Zacks Equity Research
Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Inflation Pressures
by Sundeep Ganoria
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -17.39% and 2.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
by Zacks Equity Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Sundeep Ganoria
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 20% and 99.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
Bausch Health (BHC) Beats Q4 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 17.59% and 0.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -75.00% and -71.55%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 63.27% and -59.15%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SolGel Technologies Ltd. (SLGL) Moves 9.7% Higher: Will This Strength Last?
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SolGel Technologies Ltd. (SLGL) Stock Jumps 10.8%: Will It Continue to Soar?
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
SolGel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 12.20% and -725.03%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies (SLGL) Looks Good: Stock Adds 8.8% in Session
by Zacks Equity Research
Sol-Gel Technologies (SLGL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.